The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, ...

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan ... include GSK’s Trelegy Ellipta, which is anticipated ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma ... thanks to its ageing asthma and COPD inhaler Advair, which finally succumbed ...

Keep this leaflet with the medicine. You may need to read it again. TRELEGY ELLIPTA is a dry powder inhaler. When you breathe in using the inhaler, the medicine is deposited into the lungs.

Incruse Ellipta (umeclidinium) is a brand-name inhaler prescribed for chronic obstructive pulmonary disease (COPD) in adults. As with other drugs, Incruse Ellipta can cause side effects ...

The tobacco giant that makes Marlboro cigarettes has sold a UK inhaler company for a knock-down price due to what it calls an "unwarranted" backlash. Philip Morris International (PMI) has ...

Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone furoate and vilanterol) and Trelegy Ellipta (fluticasone furoate, umeclidinium ...